Stock A215380 WOOJUNG BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials WOOJUNG BIO, Inc.

Equities

A215380

KR7215380007

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-09 EDT 		5-day change 1st Jan Change
1,660 KRW -1.19% Intraday chart for WOOJUNG BIO, Inc. -0.30% -20.57%
2023 WOOJUNG BIO, Inc. announced that it has received KRW 5 billion in funding from Korea Investment Partners Co. Ltd. CI
2023 WOOJUNG BIO, Inc. announced that it expects to receive KRW 5 billion in funding from Korea Investment Partners Co. Ltd. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 51,977 56,995 114,036 80,970 38,678 27,081
Enterprise Value (EV) 1 43,184 49,830 123,462 113,122 74,363 73,651
P/E ratio -27.6 x 189 x -10 x -39.1 x -20.5 x -5.29 x
Yield - - - - - -
Capitalization / Revenue 2.19 x 1.77 x 3.05 x 2.59 x 0.82 x 0.7 x
EV / Revenue 1.82 x 1.54 x 3.31 x 3.62 x 1.58 x 1.91 x
EV / EBITDA -16.3 x 24.7 x -32.3 x -97.5 x 43.1 x 247 x
EV / FCF -5.94 x 8.53 x -4.66 x -4.58 x -13.8 x -8.19 x
FCF Yield -16.8% 11.7% -21.5% -21.8% -7.22% -12.2%
Price to Book 2.45 x 2.11 x 4.01 x 2.54 x 1.29 x 1.22 x
Nbr of stocks (in thousands) 10,044 10,614 12,093 12,873 12,958 12,958
Reference price 2 5,175 5,370 9,430 6,290 2,985 2,090
Announcement Date 19-03-01 20-02-29 21-03-01 22-03-01 23-03-01 24-02-29
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 23,758 32,290 37,344 31,238 46,918 38,616
EBITDA 1 -2,655 2,017 -3,819 -1,160 1,726 298.2
EBIT 1 -3,465 642.3 -5,404 -3,861 -2,521 -4,025
Operating Margin -14.58% 1.99% -14.47% -12.36% -5.37% -10.42%
Earnings before Tax (EBT) 1 -4,074 14.38 -10,568 -1,926 -1,866 -5,054
Net income 1 -4,617 279.6 -10,879 -1,926 -1,880 -5,054
Net margin -19.43% 0.87% -29.13% -6.16% -4.01% -13.09%
EPS 2 -187.4 28.42 -939.9 -160.9 -145.5 -395.0
Free Cash Flow 1 -7,268 5,844 -26,499 -24,716 -5,372 -8,994
FCF margin -30.59% 18.1% -70.96% -79.12% -11.45% -23.29%
FCF Conversion (EBITDA) - 289.71% - - - -
FCF Conversion (Net income) - 2,090.15% - - - -
Dividend per Share - - - - - -
Announcement Date 19-03-01 20-02-29 21-03-01 22-03-01 23-03-01 24-02-29
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 9,426 32,152 35,685 46,570
Net Cash position 1 8,793 7,164 - - - -
Leverage (Debt/EBITDA) - - -2.468 x -27.71 x 20.68 x 156.2 x
Free Cash Flow 1 -7,268 5,844 -26,499 -24,716 -5,372 -8,994
ROE (net income / shareholders' equity) -23.8% 1.18% -35.4% -5.91% -6.1% -19.6%
ROA (Net income/ Total Assets) -5.68% 0.78% -5.3% -2.84% -1.62% -2.6%
Assets 1 81,225 35,666 205,237 67,811 116,413 194,203
Book Value Per Share 2 2,113 2,550 2,349 2,475 2,322 1,719
Cash Flow per Share 2 1,144 450.0 344.0 35.80 279.0 424.0
Capex 1 4,673 2,161 15,765 36,684 11,422 843
Capex / Sales 19.67% 6.69% 42.22% 117.43% 24.34% 2.18%
Announcement Date 19-03-01 20-02-29 21-03-01 22-03-01 23-03-01 24-02-29
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
WOOJUNG BIO, INC. Stock WOOJUNG BIO, Inc.
-20.57% 16.53M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A215380 Stock
  4. Financials WOOJUNG BIO, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW